Psychopharmacology

Why psychiatrists must talk about sex: sexual dysfunction can exacerbate comorbid psychiatric disorders and contribute to medication nonadherence.

Explore 2026’s fast-moving psych med pipeline: new Alzheimer agitation option, potential novel ADHD therapy, and promising psilocybin for depression.

Post hoc SUSTAIN-1 data reveal who relapses after stopping intranasal esketamine in TRD—key risk factors guide personalized relapse-prevention plans.

Experts urge early bipolar disorder treatment, highlighting lithium’s underuse despite neuroprotective, antisuicidal benefits and evidence that delays worsen outcomes and responsiveness.

Expert analysis compares adjunctive atypical antipsychotics for MDD, highlighting lumatperone’s larger effect and minimal weight gain or akathisia.

FDA issues CRL for CTx-1301 in ADHD.

Weighing the risks and benefits of stimulants to treat ADHD.

Review the highlights from last week's meeting of the American Society for Clinical Psychopharmacology.

S. Nassir Ghaemi, MD, shares highlights from the ASCP task force consensus on psychiatric polypharmacy, emphasizing monotherapy and diagnostic reassessment.

Phase 3 at-home data show sublingual dexmedetomidine cuts severe agitation in bipolar disorder and schizophrenia, supporting FDA label expansion.

Patient selection, monitoring, and counseling on dissociation are critical to safe ketamine treatment.

Experts explain how careful pediatric psychopharmacology and early intervention protect development, curb relapse, and address substance-use risk.

Check out the pipeline updates from May!

Real-world claims show opioids remain common in fibromyalgia despite guidance, highlighting safety concerns and interest in FDA-approved non-opioid option Tonmya.

Phase 2b data show DT‑120, optimized oral LSD, delivers durable GAD remission with mostly same‑day side effects; phase 3 trials advance.

At the 2026 ASCP Annual Meeting, Eric Konofal, MD, PhD, argued that sleep assessment should become a routine part of ADHD evaluation and treatment.

Expert psychiatrists share new ASCP deprescribing guidance, tackling overprescribing, primary-care challenges, and practical tapering strategies to improve safer, patient-centered mental health care.

New real-world data in obese, antidepressant-naive patients with MDD shows bupropion edging SSRIs on remission, though rates stay low.

Investigational depression drugs target SIRT6 epigenetics, histamine H3, and AMPA.

APA session probes ADHD stimulant prescribing, contrasts population studies with RCTs, and explores education and brain effects.

Researchers at the ASCP Annual Meeting reported on how impaired brain insulin signaling may predict worsening depression severity and the links between metabolism and mood.

AI adoption in psychiatry and emerging psychedelic therapies are among the most anticipated topics at ASCP 2026, according to Benjamin Brody, MD.

David W. Goodman, MD, discusses the new ASCP consensus recommendations on when clinicians should consider deprescribing stimulants as part of good ADHD care.

John J. Miller, MD, Psychiatric Times editor in chief, looks forward to learning and sharing the late-breaking science, expert interviews, and new podcast conversations in psychopharmacology.

Explore psychopharmacologic options for personality disorders in this podcast.